Content about Oxaliplatin

January 25, 2013
New indication approved for Genentech drug

The Food and Drug Administration has approved a new use for a cancer drug made by Roche unit Genentech, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new use for a cancer drug made by Roche unit Genentech, the agency said.

The FDA announced the approval of Avastin (bevacizumab) combined with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin chemotherapy for treating colorectal cancer that has spread to other parts of the body, also known as metastatic colorectal cancer, or mCRC.

The drug is also approved for treating lung cancer, kidney cancer and brain cancer.

August 15, 2012
Teva launches generic chemotherapy drug

A division of Teva Pharmaceutical Industries has launched a generic chemotherapy drug, the company said.

IRVINE, Calif. — A division of Teva Pharmaceutical Industries has launched a generic chemotherapy drug, the company said.

Teva Health Systems announced the introduction of oxaliplatin injection in the 50-mg and 100-mg strengths.

The drug is a generic version of Sanofi's Eloxatin, which had sales of $1.7 billion during the 12-month period ended in June, according to IMS Health.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

August 9, 2012
Hospira relaunches chemotherapy drug

Hospira has relaunched a generic chemotherapy drug for the U.S. market, the generic drug maker said Thursday.

LAKE FOREST, Ill. — Hospira has relaunched a generic chemotherapy drug for the U.S. market, the generic drug maker said Thursday.

The company, which specializes in generic injectables, announced the relaunch of oxaliplatin, a version of Sanofi's Eloxatin.

August 9, 2012
Sagent Pharmaceuticals launches oxaliplatin

Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

SCHAUMBURG, Ill. — Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

Sagent announced the launch of oxaliplatin, a generic version of Sanofi's Eloxatin.

Various versions of the drug had sales of about $1.7 billion during the 12-month period ended in June, according to IMS Health.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

August 6, 2012
FDA approves Sanofi drug for colorectal cancer

The Food and Drug Administration has approved a new drug for treating colorectal cancer that has spread to other parts of the body, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating colorectal cancer that has spread to other parts of the body, the agency said Friday.

October 25, 2010
Suspending oxaliplatin sales leads to loss for Hospira

The temporary discontinuation of sales of a drug used by cancer patients led to a...

LAKE FOREST, Ill. The temporary discontinuation of sales of a drug used by cancer patients led to a slight dip in sales for Hospira during third quarter 2010, but the company nonetheless had strong sales overall, according to an earnings report released Tuesday.

 

March 11, 2010
Caraco launches colon, rectal cancer generic

Caraco Pharmaceutical Labs has launched a generic version of a drug for treating colon and...